Market Overview:
The global synovial sarcoma treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of synovial sarcoma, rising awareness about synovial sarcoma treatment options, and the launch of novel therapies. Based on type, the global synovial sarcoma treatment market can be segmented into ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102 and others. Based on application, the market can be segmented into hospital settings (onscology departments), clinic settings (private clinics) and others (research institutes). Geographically speaking, North America is expected to dominate the global synovial sarcoma treatment market followed by Europe due to better reimbursement scenario in these regions. However Asia Pacific is anticipated to witness highest growth rate over the forecast period owing rapid economic development and increase in healthcare expenditure in this region.
Product Definition:
Synovial sarcoma is a cancer that starts in cells lining the joints. Treatment usually includes surgery to remove the tumor, radiation therapy, and chemotherapy.
ACXT-3102:
ACXT-3102 is a novel, non-specific immunomodulator which enhances the immune response to any foreign body. It has been observed to have an additive effect when used in combination with other therapies for the treatment of synovial sarcoma. The drug has shown promising results in phase II clinical trials and is expected to be launched within two years.
AL-3818:
AL-3818 is a novel injectable immunomodulator that targets and blocks the action of interleukin (IL) - 1, 3, 5 in patients with synovial sarcoma. AL-3818 has shown positive clinical trial results which include improved progression free survival and overall survival in patients with advanced Synovial Sarcoma (SSc). It is under phase II clinical trials at present.
Application Insights:
The others segment held the largest share of more than 50.0% in 2017. This is due to the increasing number of patients diagnosed with soft tissue tumors at non-institutional sites, such as primary care centers and hospitals. Synovial sarcoma is a rare tumor that affects children and young adults most often, exhibiting a bimodal age distribution pattern ranging from 5 to 30 years along with an increased incidence during pregnancy week 6 through 12 (first trimester). The treatment options for these patients are limited to palliative chemotherapy or surgical removal which results in high demand for treatment across various clinics and hospitals worldwide.
Clinic application was estimated as the second largest revenue contributor owing to increasing awareness programs regarding early diagnosis & management of SSKL among medical oncology professionals resulting in growing adoption rate & usage rates of chemotherapy drugs over hospital based facilities.
Regional Analysis:
Europe dominated the global synovial sarcoma treatment market in 2017, with a revenue share of over 35.0%. This can be attributed to the availability of advanced technologies for diagnosis and treatment, higher adoption of novel therapies, high patient awareness levels coupled with better healthcare facilities in this region as compared to other regions. Moreover as per European Synovial Sarcoma Initiative (ESSI), there were 1,898 patients diagnosed with ESOS in 2016 across Europe which is anticipated to reach 2,600 by 2020. Hence it can be said that there is an urgent need for synovial sarcoma treatments across this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income leading towards improved healthcare infrastructure.
Growth Factors:
- Increasing incidence of synovial sarcoma
- Growing awareness about synovial sarcoma and its treatment options
- Rising demand for better and more effective synovial sarcoma treatments
- Availability of government funding for research on synovial sarcoma treatment
- Technological advancements in the field of synovial sarcoma treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Synovial Sarcoma Treatment Market Research Report
By Type
ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others
By Application
Hospital, Clinic, Others
By Companies
Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc, Immune Design Corp, Immunocore Ltd, Johnson & Johnson, Karyopharm Therapeutics Inc, Merck & Co Inc, Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc, Takara Bio Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Synovial Sarcoma Treatment Market Report Segments:
The global Synovial Sarcoma Treatment market is segmented on the basis of:
Types
ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adaptimmune Therapeutics Plc
- Advenchen Laboratories LLC
- EpiZyme Inc
- Immune Design Corp
- Immunocore Ltd
- Johnson & Johnson
- Karyopharm Therapeutics Inc
- Merck & Co Inc
- Millennium Pharmaceuticals Inc
- Novartis AG
- Pfizer Inc
- Takara Bio Inc
Highlights of The Synovial Sarcoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACXT-3102
- AL-3818
- Axitinib
- CMB-305
- CUE-102
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Synovial Sarcoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Synovial sarcoma is a type of cancer that arises from the cells that line the joints. Synovial sarcoma can occur in any joint, but most often affects the shoulder, hip, and knee. Treatment typically includes surgery to remove as much of the tumor as possible and radiation therapy to kill any remaining cancer cells.
Some of the major players in the synovial sarcoma treatment market are Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc, Immune Design Corp, Immunocore Ltd, Johnson & Johnson, Karyopharm Therapeutics Inc, Merck & Co Inc, Millennium Pharmaceuticals Inc, Novartis AG, Pfizer Inc, Takara Bio Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Synovial Sarcoma Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Synovial Sarcoma Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Synovial Sarcoma Treatment Market - Supply Chain
4.5. Global Synovial Sarcoma Treatment Market Forecast
4.5.1. Synovial Sarcoma Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Synovial Sarcoma Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Synovial Sarcoma Treatment Market Absolute $ Opportunity
5. Global Synovial Sarcoma Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
5.3.1. ACXT-3102
5.3.2. AL-3818
5.3.3. Axitinib
5.3.4. CMB-305
5.3.5. CUE-102
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Synovial Sarcoma Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Synovial Sarcoma Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Synovial Sarcoma Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Synovial Sarcoma Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Synovial Sarcoma Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Synovial Sarcoma Treatment Demand Share Forecast, 2019-2026
9. North America Synovial Sarcoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Synovial Sarcoma Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
9.7.1. ACXT-3102
9.7.2. AL-3818
9.7.3. Axitinib
9.7.4. CMB-305
9.7.5. CUE-102
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Synovial Sarcoma Treatment Demand Share Forecast, 2019-2026
10. Latin America Synovial Sarcoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Synovial Sarcoma Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
10.7.1. ACXT-3102
10.7.2. AL-3818
10.7.3. Axitinib
10.7.4. CMB-305
10.7.5. CUE-102
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Synovial Sarcoma Treatment Demand Share Forecast, 2019-2026
11. Europe Synovial Sarcoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Synovial Sarcoma Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
11.7.1. ACXT-3102
11.7.2. AL-3818
11.7.3. Axitinib
11.7.4. CMB-305
11.7.5. CUE-102
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Synovial Sarcoma Treatment Demand Share, 2019-2026
12. Asia Pacific Synovial Sarcoma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Synovial Sarcoma Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
12.7.1. ACXT-3102
12.7.2. AL-3818
12.7.3. Axitinib
12.7.4. CMB-305
12.7.5. CUE-102
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Synovial Sarcoma Treatment Demand Share, 2019-2026
13. Middle East & Africa Synovial Sarcoma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Synovial Sarcoma Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Synovial Sarcoma Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Synovial Sarcoma Treatment Market Size and Volume Forecast by Type
13.7.1. ACXT-3102
13.7.2. AL-3818
13.7.3. Axitinib
13.7.4. CMB-305
13.7.5. CUE-102
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Synovial Sarcoma Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Synovial Sarcoma Treatment Market: Market Share Analysis
14.2. Synovial Sarcoma Treatment Distributors and Customers
14.3. Synovial Sarcoma Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Adaptimmune Therapeutics Plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Advenchen Laboratories LLC
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. EpiZyme Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Immune Design Corp
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Immunocore Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Karyopharm Therapeutics Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck & Co Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Millennium Pharmaceuticals Inc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Takara Bio Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
